Tvardi Therapeutics (TVRD) EBIAT: 2013-2017
Historic EBIAT for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to -$12.4 million.
- Tvardi Therapeutics' EBIAT fell 7.81% to -$12.4 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$65.9 million, marking a year-over-year decrease of 47.01%. This contributed to the annual value of -$57.3 million for FY2016, which is 132.00% down from last year.
- Per Tvardi Therapeutics' latest filing, its EBIAT stood at -$12.4 million for Q3 2017, which was down 33.81% from -$9.3 million recorded in Q2 2017.
- In the past 5 years, Tvardi Therapeutics' EBIAT ranged from a high of $5.3 million in Q2 2013 and a low of -$22.2 million during Q1 2017.
- In the last 3 years, Tvardi Therapeutics' EBIAT had a median value of -$10.7 million in 2016 and averaged -$11.4 million.
- In the last 5 years, Tvardi Therapeutics' EBIAT crashed by 168.30% in 2014 and then climbed by 28.87% in 2017.
- Quarterly analysis of 5 years shows Tvardi Therapeutics' EBIAT stood at -$2.1 million in 2013, then slumped by 99.33% to -$4.2 million in 2014, then tumbled by 128.43% to -$9.5 million in 2015, then plummeted by 130.55% to -$22.0 million in 2016, then dropped by 7.81% to -$12.4 million in 2017.
- Its last three reported values are -$12.4 million in Q3 2017, -$9.3 million for Q2 2017, and -$22.2 million during Q1 2017.